You have 9 free searches left this month | for more free features.

idelalisib

Showing 1 - 25 of 37

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Diffuse Large B Cell Lymphoma Trial in Denmark, Sweden (Idelalisib)

Completed
  • Diffuse Large B Cell Lymphoma
  • Idelalisib
  • Aarhus C, Denmark
  • +5 more
Oct 12, 2021

Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma Trial in United

Terminated
  • Previously Untreated Pancreatic Ductal Adenocarcinoma
  • Relapsed/Refractory Pancreatic Ductal Adenocarcinoma
  • Idelalisib
  • +2 more
  • Scottsdale, Arizona
  • +8 more
Mar 31, 2021

Acute Lymphoblastic Leukemia Trial in Spain (Idelalisib)

Terminated
  • Acute Lymphoblastic Leukemia
  • Idelalisib
  • Badalona, Spain
  • +11 more
Sep 2, 2021

Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma Trial in Aichi, Miyagi, Tokyo (Idelalisib)

Completed
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Idelalisib
  • Aichi, Japan
  • +2 more
Feb 24, 2021

Chronic Lymphocytic Leukemia Trial in Germany (Tirabrutinib, Idelalisib, Obinutuzumab)

Completed
  • Chronic Lymphocytic Leukemia
  • Frankfurt, Brandenburg, Germany
  • +13 more
Dec 24, 2021

Recurrent Chronic Lymphoid Leukemia Trial in Boston (ACY-1215, Ibrutinib, Idelalisib)

Active, not recruiting
  • Recurrent Chronic Lymphoid Leukemia
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jun 13, 2022

Chronic Lymphocytic Leukemia (CLL) Trial in Columbus, Salt Lake City (Idelalisib, BI 836826)

Terminated
  • Chronic Lymphocytic Leukemia (CLL)
  • Idelalisib
  • BI 836826
  • Columbus, Ohio
  • +1 more
Nov 23, 2020

Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide

Completed
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +2 more
  • Tafasitamab
  • +2 more
  • Jacksonville, Florida
  • +16 more
Dec 10, 2021

Myelofibrosis Trial in Stanford, Ann Arbor (Idelalisib, Ruxolitinib)

Terminated
  • Myelofibrosis
  • Stanford, California
  • +1 more
Aug 31, 2020

Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Worldwide (Loncastuximab Tesirine, Idelalisib)

Active, not recruiting
  • Relapsed Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Loncastuximab Tesirine
  • Idelalisib
  • Las Vegas, Nevada
  • +33 more
Jul 26, 2022

Lymphoid Malignancies Trial in Amsterdam (Idelalisib)

Terminated
  • Lymphoid Malignancies
  • Idelalisib
  • Amsterdam, Netherlands
    (unnamed)
Feb 18, 2020

Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in United States (Idelalisib,

Completed
  • Indolent Non-Hodgkin's Lymphoma
  • +2 more
  • Idelalisib
  • +8 more
  • Huntsville, Alabama
  • +10 more
Feb 22, 2021

Follicular Lymphoma, Mantle Cell Lymphoma Trial in Worldwide (BCL201, Idelalisib)

Completed
  • Follicular Lymphoma, Mantle Cell Lymphoma
  • New York, New York
  • +6 more
Feb 21, 2020

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma Trial in United States (Entospletinib,

Terminated
  • Chronic Lymphocytic Leukemia
  • +3 more
  • La Jolla, California
  • +12 more
May 18, 2020

Follicular Lymphoma Trial in Worldwide (Idelalisib)

Active, not recruiting
  • Follicular Lymphoma
  • Idelalisib
  • Woodville South, South Australia, Australia
  • +65 more
Aug 24, 2022

Idelalisib in Patients With Refractory Follicular Lymphoma

Completed
  • Follicular Non-Hodgkin's Lymphoma Refractory
  • Idelalisib
  • Antwerpen, Belgium
  • +87 more
Nov 16, 2021

Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin Trial in United States (Idelalisib)

Terminated
  • Chronic Lymphocytic Leukemia
  • Lymphoma, Non-Hodgkin
  • Idelalisib
  • Huntsville, Alabama
  • +17 more
Aug 22, 2019

Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in United States (Idelalisib, Rituximab)

Terminated
  • Follicular Lymphoma
  • Small Lymphocytic Lymphoma
  • Idelalisib
  • Rituximab
  • Long Beach, California
  • +5 more
May 1, 2019

Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in Palo Alto, New York (Idelalisib)

Completed
  • Indolent Non-Hodgkin's Lymphoma
  • +3 more
  • Idelalisib
  • Palo Alto, California
  • +1 more
Oct 19, 2018

Chronic Lymphocytic Leukaemia Treated With Idelalisib and

Completed
  • Chronic Lymphocytic Leukaemia
  • Dublin, Ireland
  • +15 more
Apr 11, 2019

DLBCL, Mediastinal B-cell Lymphoma Trial in Worldwide (Idelalisib, Rituximab, Ifosfamide)

Withdrawn
  • Diffuse Large B-Cell Lymphoma
  • Mediastinal B-cell Lymphoma
  • Idelalisib
  • +4 more
  • Lille, France
  • +6 more
Dec 7, 2018

Chronic Lymphocytic Leukemia Trial in Worldwide (Idelalisib)

Terminated
  • Chronic Lymphocytic Leukemia
  • Idelalisib
  • Huntsville, Alabama
  • +44 more
Aug 12, 2019

Hodgkin Lymphoma Trial in New York, Houston, Seattle (Idelalisib)

Completed
  • Hodgkin Lymphoma
  • Idelalisib
  • New York, New York
  • +2 more
Oct 19, 2018

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) Trial in United States (Idelalisib, Rituximab)

Terminated
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • La Jolla, California
  • +5 more
Oct 19, 2018

Chronic Lymphocytic Leukemia Trial in Worldwide (Idelalisib, Rituximab, Bendamustine)

Completed
  • Chronic Lymphocytic Leukemia
  • Idelalisib
  • +3 more
  • Huntsville, Alabama
  • +105 more
Mar 2, 2020